These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 37425694)

  • 1. Persistent biofluid small molecule alterations induced by
    Dean DA; Roach J; vonBargen RU; Xiong Y; Kane SS; Klechka L; Wheeler K; Sandoval MJ; Lesani M; Hossain E; Katemauswa M; Schaefer M; Harris M; Barron S; Liu Z; Pan C; McCall LI
    bioRxiv; 2023 Jun; ():. PubMed ID: 37425694
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Persistent Biofluid Small-Molecule Alterations Induced by
    Dean DA; Roach J; Ulrich vonBargen R; Xiong Y; Kane SS; Klechka L; Wheeler K; Jimenez Sandoval M; Lesani M; Hossain E; Katemauswa M; Schaefer M; Harris M; Barron S; Liu Z; Pan C; McCall LI
    ACS Infect Dis; 2023 Nov; 9(11):2173-2189. PubMed ID: 37883691
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Localized cardiac small molecule trajectories and persistent chemical sequelae in experimental Chagas disease.
    Liu Z; Ulrich vonBargen R; Kendricks AL; Wheeler K; Leão AC; Sankaranarayanan K; Dean DA; Kane SS; Hossain E; Pollet J; Bottazzi ME; Hotez PJ; Jones KM; McCall LI
    Nat Commun; 2023 Oct; 14(1):6769. PubMed ID: 37880260
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Sequential combined treatment with allopurinol and benznidazole in the chronic phase of Trypanosoma cruzi infection: a pilot study.
    Perez-Mazliah DE; Alvarez MG; Cooley G; Lococo BE; Bertocchi G; Petti M; Albareda MC; Armenti AH; Tarleton RL; Laucella SA; Viotti R
    J Antimicrob Chemother; 2013 Feb; 68(2):424-37. PubMed ID: 23104493
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Trypanocidal drugs for late-stage, symptomatic Chagas disease (Trypanosoma cruzi infection).
    Vallejo M; Reyes PP; Martinez Garcia M; Gonzalez Garay AG
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD004102. PubMed ID: 33305846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Candimine from Hippeastrum escoipense (Amaryllidaceae): Anti-Trypanosoma cruzi activity and synergistic effect with benznidazole.
    Ortiz JE; Piñeiro M; Martinez-Peinado N; Barrera P; Sosa M; Bastida J; Alonso-Padilla J; Feresin GE
    Phytomedicine; 2023 Jun; 114():154788. PubMed ID: 37037085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. In vitro and in vivo antiparasitic activity of Physalis angulata L. concentrated ethanolic extract against Trypanosoma cruzi.
    Meira CS; Guimarães ET; Dos Santos JA; Moreira DR; Nogueira RC; Tomassini TC; Ribeiro IM; de Souza CV; Ribeiro Dos Santos R; Soares MB
    Phytomedicine; 2015 Oct; 22(11):969-74. PubMed ID: 26407938
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Experimental Combination Therapy with Amiodarone and Low-Dose Benznidazole in a Mouse Model of Trypanosoma cruzi Acute Infection.
    Barbosa JMC; Pedra Rezende Y; de Melo TG; de Oliveira G; Cascabulho CM; Pereira ENGDS; Daliry A; Salem KS
    Microbiol Spectr; 2022 Feb; 10(1):e0185221. PubMed ID: 35138142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Anti-parasitic effect of vitamin C alone and in combination with benznidazole against Trypanosoma cruzi.
    Puente V; Demaria A; Frank FM; Batlle A; Lombardo ME
    PLoS Negl Trop Dis; 2018 Sep; 12(9):e0006764. PubMed ID: 30240395
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacokinetics of Benznidazole in Experimental Chronic Chagas Disease Using the Swiss Mouse-Berenice-78 Trypanosoma cruzi Strain Model.
    de Jesus SM; Pinto L; Moreira FL; Nardotto GHB; Cristofoletti R; Perin L; Fonseca KDS; Barbêdo P; Bandeira LC; Vieira PMA; Carneiro CM
    Antimicrob Agents Chemother; 2021 Jan; 65(2):. PubMed ID: 33168611
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Trypanosoma cruzi Produces the Specialized Proresolving Mediators Resolvin D1, Resolvin D5, and Resolvin E2.
    Colas RA; Ashton AW; Mukherjee S; Dalli J; Akide-Ndunge OB; Huang H; Desruisseaux MS; Guan F; Jelicks LA; Matos Dos Santos F; Nagajyothi J; Zingman MA; Reyes J; Weiss LM; Serhan CN; Tanowitz HB
    Infect Immun; 2018 Apr; 86(4):. PubMed ID: 29358332
    [No Abstract]   [Full Text] [Related]  

  • 12. Low-dose benznidazole treatment results in parasite clearance and attenuates heart inflammatory reaction in an experimental model of infection with a highly virulent Trypanosoma cruzi strain.
    Cevey ÁC; Mirkin GA; Penas FN; Goren NB
    Int J Parasitol Drugs Drug Resist; 2016 Apr; 6(1):12-22. PubMed ID: 26862474
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Impact of benznidazole treatment on the functional response of Trypanosoma cruzi antigen-specific CD4+CD8+ T cells in chronic Chagas disease patients.
    Pérez-Antón E; Egui A; Thomas MC; Puerta CJ; González JM; Cuéllar A; Segovia M; López MC
    PLoS Negl Trop Dis; 2018 May; 12(5):e0006480. PubMed ID: 29750791
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Alterations to the Cardiac Metabolome Induced by Chronic
    Hoffman K; Liu Z; Hossain E; Bottazzi ME; Hotez PJ; Jones KM; McCall LI
    ACS Infect Dis; 2021 Jun; 7(6):1638-1649. PubMed ID: 33843195
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pentamidine antagonizes the benznidazole's effect in vitro, and lacks of synergy in vivo: Implications about the polyamine transport as an anti-Trypanosoma cruzi target.
    Seguel V; Castro L; Reigada C; Cortes L; Díaz MV; Miranda MR; Pereira CA; Lapier M; Campos-Estrada C; Morello A; Kemmerling U; Maya JD; López-Muñoz R
    Exp Parasitol; 2016 Dec; 171():23-32. PubMed ID: 27729250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Localized cardiac metabolic trajectories and post-infectious metabolic sequelae in experimental Chagas disease.
    Liu Z; Ulrich R; Kendricks AL; Wheeler K; Leão AC; Pollet J; Bottazzi ME; Hotez P; Gusovsky F; Jones KM; McCall LI
    Res Sq; 2023 Jan; ():. PubMed ID: 36711878
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vaccine-linked chemotherapy improves cardiac structure and function in a mouse model of chronic Chagas disease.
    Jones KM; Mangin EN; Reynolds CL; Villanueva LE; Cruz JV; Versteeg L; Keegan B; Kendricks A; Pollet J; Gusovsky F; Bottazzi ME; Hotez PJ
    Front Cell Infect Microbiol; 2023; 13():1106315. PubMed ID: 36844399
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Therapeutic responses to different anti-Trypanosoma cruzi drugs in experimental infection by benznidazole-resistant parasite stock.
    Caldas S; Caldas IS; Cecílio AB; Diniz LD; Talvani A; Ribeiro I; Bahia MT
    Parasitology; 2014 Jul; ():1-10. PubMed ID: 25045804
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Antitrypanosomal Treatment with Benznidazole Is Superior to Posaconazole Regimens in Mouse Models of Chagas Disease.
    Khare S; Liu X; Stinson M; Rivera I; Groessl T; Tuntland T; Yeh V; Wen B; Molteni V; Glynne R; Supek F
    Antimicrob Agents Chemother; 2015 Oct; 59(10):6385-94. PubMed ID: 26239982
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Parasitaemia and parasitic load are limited targets of the aetiological treatment to control the progression of cardiac fibrosis and chronic cardiomyopathy in Trypanosoma cruzi-infected dogs.
    Caldas IS; Menezes APJ; Diniz LF; Nascimento ÁFDSD; Novaes RD; Caldas S; Bahia MT
    Acta Trop; 2019 Jan; 189():30-38. PubMed ID: 30290285
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.